1. Home
  2. OLP vs ALLO Comparison

OLP vs ALLO Comparison

Compare OLP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$22.62

Market Cap

503.2M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.13

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
ALLO
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.2M
539.4M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
OLP
ALLO
Price
$22.62
$2.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
15
Target Price
$26.75
$8.35
AVG Volume (30 Days)
52.1K
14.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
7.88%
N/A
EPS Growth
N/A
34.09
EPS
1.15
N/A
Revenue
$82,740,000.00
N/A
Revenue This Year
$11.98
N/A
Revenue Next Year
$3.71
$142,416.42
P/E Ratio
$19.80
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$0.86
52 Week High
$25.90
$4.46

Technical Indicators

Market Signals
Indicator
OLP
ALLO
Relative Strength Index (RSI) 46.36 42.55
Support Level $22.11 $1.70
Resistance Level $23.42 $2.71
Average True Range (ATR) 0.43 0.32
MACD -0.02 -0.05
Stochastic Oscillator 18.10 10.54

Price Performance

Historical Comparison
OLP
ALLO

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: